Financial toxicity among US adults with rheumatic disease and prior cancer: a nationally representative cross-sectional study
Authors:
- 23 September 2026
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 6367-6376
Abstract
Objective Financial toxicity (FT), the financial burden of accessing health care, is well known in oncology care and increasingly seen in rheumatic disease (RD). We compared FT among adults with neither condition, RD only, cancer only, and both. Methods We used data from the National Health Interview Survey, a nationally representative sample of US adults from 2019 to 2023. Adults were categorized by self-reported diagnosis of a RD, including arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia, and cancer. FT was defined as one or more of the following: financial distress, difficulty paying bills, delayed or forgone care, cost related medication nonadherence, or food insecurity. Weighted logistic regressions examined associations between disease groups and FT, adjusting for demographics, comorbidities, and insurance. Analyses were stratified by age (< 65 versus ≥ 65 years). Results Among 149,905 adults, 100,652 had neither condition, 10,094 had cancer only, 30,446 had RD only, and 8,713 had both. Those with both conditions were older and had the highest multimorbidity. Among adults < 65 years, FT was highest in RD only and both groups (63.9% and 64.3%) vs neither (54.0%). Cost-related medication nonadherence was more common in RD. Among adults ≥ 65 years, FT remained highest in RD only (41.4%). In adjusted analyses, RD only and both conditions were associated with increased FT, whereas cancer only was not. Conclusion RD is associated with substantial financial burden across domains. These findings highlight the need for greater recognition of financial toxicity in rheumatology. Key Points • This study provides the first nationally representative analysis to characterize and directly compare financial toxicity across adults with rheumatic disease (RD) only, cancer only, and the co-occurrence of both conditions. • Living with a RD is a primary and persistent driver of financial hardship across all adult age groups, extending the financial toxicity literature beyond its traditional focus on oncology. • These findings highlight an under-recognized burden in rheumatology and underscore the need for greater attention to identifying and addressing financial hardship in this population.Keywords
This publication has 41 references indexed in Scilit:
- Financial Distress and Its Determinants in Rheumatoid ArthritisArthritis Care & Research, 2025
- Effects of Social Vulnerability and Environmental Burden on Care Fragmentation and Social Needs Among Individuals With Rheumatic ConditionsArthritis Care & Research, 2024
- Financial toxicity among cancer survivors: a conceptual model based on a feedback perspectiveSupportive Care in Cancer, 2023
- Association of Chronic Disease With Patient Financial Outcomes Among Commercially Insured AdultsJAMA Internal Medicine, 2022
- Medical financial hardship among cancer survivors in the United StatesCancer, 2019
- Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategiesJournal of Surgical Oncology, 2019
- Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta‐AnalysisArthritis Care & Research, 2018
- Coverage for High‐Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part DArthritis & Rheumatology, 2015
- Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care?Cancer, 2013
- Changes in Financial Burdens for Health CareJAMA, 2006